Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gritstone Bio Inc (GRTS)

Gritstone Bio Inc (GRTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Gritstone Bio Inc 5959 HORTON STREET SUITE 300 EMERYVILLE CA 94608 USA

www.gritstonebio.com Employees: 231 P: 510-871-6100

Description:

Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient's tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients' TSNA to drive the patient's immune system to attack and destroy tumors.

Key Statistics

Overview:

Market Capitalization, $K 3,496
Enterprise Value, $K -21,654
Shares Outstanding, K 108,569
Annual Sales, $ 16,340 K
Annual Net Income, $ -138,490 K
Last Quarter Sales, $ 920 K
Last Quarter Net Income, $ -23,400 K
EBIT, $ -136,460 K
EBITDA, $ -130,150 K
60-Month Beta 0.49
% of Insider Shareholders 4.61%
% of Institutional Shareholders 48.46%
Float, K 103,564
% Float 95.39%
Short Volume Ratio 0.49

Growth:

1-Year Return -98.41%
3-Year Return -99.71%
5-Year Return -99.60%
5-Year Revenue Growth 1,273.11%
5-Year Earnings Growth 83.47%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.16 on 08/13/24
Next Earnings Date 11/13/24
Earnings Per Share ttm -1.09
EPS Growth vs. Prev Qtr 52.94%
EPS Growth vs. Prev Year 48.39%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

GRTS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -328.51%
Return-on-Assets % -82.53%
Profit Margin % -847.55%
Debt/Equity 1.83
Price/Sales 0.34
Price/Cash Flow N/A
Price/Book 0.16
Book Value/Share 0.20
Interest Coverage -33.28
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar